Tan Chelsea Qiu Lin, Wu Duoduo, Toh Xin Yun, Lim Blanche Xiaohong, Shih Kendrick Co, Tong Louis, Lim Chris Hong Long
Department of Ophthalmology, National University Hospital, Singapore 119228, Singapore.
Lee Kong Chian School of Medicine, National Technological University, Singapore 308232, Singapore.
Life (Basel). 2025 Mar 17;15(3):484. doi: 10.3390/life15030484.
Diquafosol sodium is a purinergic P2Y receptor agonist that is garnering much interest for its potential therapeutic benefits in ocular surface management. This review provides a comprehensive analysis of diquafosol's pharmacology, clinical effectiveness, and role in the evolving landscape of ocular surface management. Future research should focus on optimising formulations, treatment duration, and exploring potential combination therapies to maximise therapeutic outcomes. By targeting underlying pathophysiological mechanisms, diquafosol represents a significant advancement in ocular surface management and a valuable addition to existing therapies.
地夸磷索钠是一种嘌呤能P2Y受体激动剂,因其在眼表治疗方面的潜在益处而备受关注。本综述全面分析了地夸磷索的药理学、临床疗效以及在不断发展的眼表治疗领域中的作用。未来的研究应集中于优化制剂、治疗时长,并探索潜在的联合治疗方法,以实现最佳治疗效果。通过针对潜在的病理生理机制,地夸磷索代表了眼表治疗的重大进展,也是现有治疗方法的宝贵补充。